KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.
Checked against the public recordLast updated May 13, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Kadmon Corporation, LLC
- Interventions being studied
- Drug: KD019; Drug: Erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
For Eligibility subjects must have: * failed one or two previous courses of therapy. * have no active brain metastasis. Treated non-active brain metastasis are acceptable. * cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva \[erlotinib\] or Iressa \[gefitinib\]) in the past. * has demonstrated progressive disease.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Yale Cancer CenterNew Haven, Connecticut
- San Juan Oncology AssociatesFarmington, New Mexico
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 13, 2022. Always confirm current availability with the study team.